Insmed (NASDAQ:INSM) Issues Earnings Results

Insmed (NASDAQ:INSM) posted its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15), Zacks reports. The business had revenue of $104.44 million during the quarter, compared to analysts’ expectations of $102.31 million. Insmed updated its FY 2025 guidance to EPS.

Insmed Stock Down 0.6 %

Shares of INSM traded down $0.53 during trading hours on Friday, reaching $83.09. 615,388 shares of the stock traded hands, compared to its average volume of 1,885,705. Insmed has a 52 week low of $21.92 and a 52 week high of $84.91. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a fifty day simple moving average of $74.11 and a 200 day simple moving average of $73.52. The company has a market cap of $14.86 billion, a price-to-earnings ratio of -14.97 and a beta of 1.11.

Insider Buying and Selling at Insmed

In other Insmed news, CEO William Lewis sold 2,978 shares of Insmed stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $63.36, for a total value of $188,686.08. Following the sale, the chief executive officer now owns 392,589 shares of the company’s stock, valued at approximately $24,874,439.04. The trade was a 0.75 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total transaction of $7,291,200.00. Following the sale, the insider now owns 97,083 shares of the company’s stock, valued at approximately $7,766,640. The trade was a 48.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 532,207 shares of company stock worth $41,400,465. Insiders own 4.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Truist Financial reiterated a “buy” rating and set a $105.00 target price (up previously from $100.00) on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. increased their price objective on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research report on Friday, February 7th. Stifel Nicolaus decreased their target price on Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday. Guggenheim increased their price target on Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Finally, Morgan Stanley boosted their price objective on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $90.79.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.